

Supplementary Materials:

Digital Pathology and PD-L1 Testing in Non Small Cell Lung Cancer: A Workshop Record

Fabio Pagni, Umberto Malapelle, Claudio Doglioni, Gabriella Fontanini, Filippo Frassetto, Paolo Graziano, Antonio Marchetti, Elena Guerini Rocco, Pasquale Pisapia, Elena Vigliar, Fiamma Buttitta, Marta Jaconi, Nicola Fusco, Massimo Barberis and Giancarlo Troncone

Table S1. Original PD-L1 evaluation, expert board consensus and prevalent scoring for every group; discrepancies between the original evaluation and the panel are highlighted in orange; participants errors in yellow.

CASES	ORIGINAL INSTITUTION	EXPERT BOARD	ORANGE	RED	VIOLET	GREEN	PINK	BLUE	YELLOW
1	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%
2	≥50%	≥50%	1-49%	≥50%	≥50%	≥50%	≥50%	≥50%	1-49%
3	<1%	<1%	<1%	<1%	<1%	<1%	<1%	1-49%	<1%
4	1-49%	1-49%	<1%	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%
5	≥50%	≥50%	≥50%	≥50%	≥50%	≥50%	≥50%	≥50%	≥50%
6	<1%	<1%	<1%	1-49%	1-49%	<1%	1-49%	<1%	1-49%
7	1-49%	≥50%	≥50%	≥50%	≥50%	≥50%	≥50%	≥50%	≥50%
8	≥50%	≥50%	≥50%	≥50%	≥50%	≥50%	≥50%	≥50%	≥50%
9	1-49%	1-49%	1-49%	1-49%	1-49%	<1%	1-49%	1-49%	<1%
10	<1%	<1%	<1%	1-49%	<1%	<1%	<1%	<1%	<1%
11	1-49%	1-49%	1-49%	1-49%	1-49%	<1%	1-49%	<1%	<1%
12	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%
14	≥50%	≥50%	≥50%	≥50%	≥50%	≥50%	≥50%	≥50%	≥50%
15	≥50%	≥50%	≥50%	≥50%	≥50%	≥50%	≥50%	≥50%	≥50%
16	<1%	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%
17	1-49%	1-49%	<1%	1-49%	1-49%	1-49%	1-49%	<1%	1-49%
20	≥50%	≥50%	≥50%	≥50%	≥50%	≥50%	≥50%	≥50%	≥50%
22	1-49%	<1%	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%
30	<1%	<1%	<1%	<1%	<1%	<1%	<1%	<1%	<1%
33	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%
34	≥50%	≥50%	≥50%	≥50%	≥50%	≥50%	≥50%	≥50%	≥50%
35	<1%	<1%	<1%	<1%	<1%	<1%	<1%	<1%	<1%
36	<1%	<1%	<1%	<1%	<1%	<1%	<1%	<1%	1-49%
37	≥50%	≥50%	1-49%	1-49%	1-49%	1-49%	≥50%	1-49%	≥50%
38	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%
41	<1%	1-49%	1-49%	1-49%	1-49%	1-49%	<1%	1-49%	1-49%
45	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%
50	≥50%	1-49%	1-49%	≥50%	1-49%	1-49%	≥50%	≥50%	1-49%
51	≥50%	1-49%	≥50%	≥50%	1-49%	1-49%	1-49%	≥50%	≥50%
52	≥50%	1-49%	1-49%	≥50%	≥50%	≥50%	1-49%	≥50%	1-49%
54	<1%	1-49%	1-49%	≥50%	1-49%	1-49%	1-49%	1-49%	1-49%
55	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%




Table S3. Performances by histotype.

	R(n=5)	Y (n=5)	O (n=5)	V(n=5)	B (n=6)	P(n=6)	G(n=5)
Adenocarcinoma (n = 22)							
1	>			<	<		<
2							
4	<		<(3)		>(1);<(1)	<	
5							
6							
7							
9		<(3)		>	<		<(3)
10							
11	<(1); >(1)	<(4)	<(2)	<	<(4)	<(2)	<(5)
12				>			>(2)
14							
15							
22							
30							
34							
35							
36							
41						<(5)	
50	>(3)	>(2)	>(2); <(1)		>(4)	>(4)	>(2)
52	>(4)			>(5)	>(3)	>(2)	>3
54	>(4)					>(1); <(1)	
55	>						
Squamous cell carcinoma / NSCLC, NOS (n = 10)							
3							
8							
16	>				>		>
17	<		<(3)		<(4)		<(2)
20							
33	>						
37							
38				<			<(2)
45							
51	>(5)	>(3)	>(3); <(1)		>(5)	>(2)	>

Table S4. Performances by clone.

	R (n=5)	Y (n=5)	O (n=5)	V (n=5)	B (n=6)	P (n=6)	G (n=5)
22C3 (n = 23)							
1	>			<	<		<
2							
3							
4	<		<(3)		>(1);<(1)	<	
5							
6							
7							
8							
9		<(3)		>	<		<(3)
10							
11	<(1); >(1)	<(4)	<(2)	<	<(4)	<(2)	<(5)
12				>			>(2)
14							
15							
16	>				>		>
17	<		<(3)		<(4)		<(2)
20							
22							
33	>						
34							
35							
54	>(4)					>(1); <(1)	
55	>						
SP263 (n = 9)							
30							
36							
37							
38				<			<(2)
41						<(5)	
45							
50	>(3)	>(2)	>(2); <(1)		>(4)	>(4)	>(2)
51	>(5)	>(3)	>(3); <(1)		>(5)	>(2)	>
52	>(4)			>(5)	>(3)	>(2)	>3